Trails Edge Capital Partners LP Acquires Shares of 1,443,333 Aura Biosciences, Inc. $AURA

Trails Edge Capital Partners LP bought a new stake in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,443,333 shares of the company's stock, valued at approximately $10,247,665. Aura Biosciences makes up approximately 0.0% of Trails Edge Capital Partners LP's investment portfolio, making the stock its 24th biggest position. Trails Edge Capital Partners LP owned approximately 1.39% of Aura Biosciences at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Dynamic Technology Lab Private Ltd bought a new position in shares of Aura Biosciences during the first quarter valued at $137,000. Invesco Ltd. purchased a new position in shares of Aura Biosciences in the second quarter worth about $76,000. Nantahala Capital Management LLC lifted its stake in Aura Biosciences by 67.1% during the second quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company's stock worth $13,257,000 after purchasing an additional 850,000 shares in the last quarter. Ameriprise Financial Inc. raised its stake in Aura Biosciences by 31.1% during the 2nd quarter. Ameriprise Financial Inc. now owns 84,558 shares of the company's stock worth $529,000 after acquiring an additional 20,065 shares in the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Aura Biosciences during the 2nd quarter worth approximately $102,000. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Aura Biosciences

In other Aura Biosciences news, insider Anthony S. Gibney sold 12,824 shares of the company's stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $6.42, for a total transaction of $82,330.08. Following the completion of the transaction, the insider owned 265,354 shares of the company's stock, valued at $1,703,572.68. This represents a 4.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 1.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Wall Street Zen downgraded Aura Biosciences from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. Weiss Ratings upgraded shares of Aura Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, July 14th. HC Wainwright cut their price target on shares of Aura Biosciences from $24.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, August 11th. Finally, Leerink Partners set a $17.00 price target on Aura Biosciences in a research note on Tuesday, May 12th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $17.50.

Aura Biosciences Trading Down 3.9%

AURA traded down $0.30 on Friday, reaching $7.40. The stock had a trading volume of 441,207 shares, compared to its average volume of 475,336. Aura Biosciences, Inc. has a 12-month low of $4.73 and a 12-month high of $9.53. The company has a market cap of $767.42 million, a P/E ratio of -4.23 and a beta of 0.40. The business's 50-day moving average price is $7.28 and its two-hundred day moving average price is $6.89.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.10). As a group, analysts predict that Aura Biosciences, Inc. will post -1.61 earnings per share for the current year.

Aura Biosciences Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.